The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

被引：0
|
作者：
Christian S. Thudium
Anne C. Bay-Jensen
Suntara Cahya
Ernst R. Dow
Morten A. Karsdal
Alisa E. Koch
Wenling Zhang
Robert J. Benschop
机构：
[1] Nordic Bioscience,
[2] Biomarkers and Research,undefined
[3] Eli Lilly and Company,undefined
来源：
Arthritis Research & Therapy | / 22卷
关键词：
Biomarkers; Baricitinib; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
    Thudium, Christian S.
    Bay-Jensen, Anne C.
    Cahya, Suntara
    Dow, Ernst R.
    Karsdal, Morten A.
    Koch, Alisa E.
    Zhang, Wenling
    Benschop, Robert J.
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [2] Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis
    Dabal, Tracey D.
    Haltom, Matthew B.
    Patel, Puja P.
    Son, Christine K.
    Joglekar, Kiran P.
    Groeschell, Charles M.
    Chumpia, Mason M.
    Kamal, Sehrish F.
    Seth, Ankur
    Jackson, Christopher D.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (05) : 288 - 292
  • [3] A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis
    Schlueter, Max
    Rouse, Peter
    Pitcher, Ashley
    Graham-Clarke, Peita Louise
    Nicolay, Claudia
    Fakhouri, Walid
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 221 - 228
  • [4] Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
    Sumit Kunwar
    Christopher E. Collins
    Florina Constantinescu
    Clinical Rheumatology, 2018, 37 : 2611 - 2620
  • [5] Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
    Kunwar, Sumit
    Collins, Christopher E.
    Constantinescu, Florina
    CLINICAL RHEUMATOLOGY, 2018, 37 (10) : 2611 - 2620
  • [6] A comparison of Janus kinase inhibitor safety in rheumatoid arthritis
    Nash, Peter
    Lim, Irwin
    Marabani, Mona
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 : 3 - 14
  • [7] BARICITINIB Tyrosine-Protein Kinase JAK1/JAK2 Inhibitor Treatment of Rheumatoid Arthritis
    Gras, Jordi
    DRUGS OF THE FUTURE, 2013, 38 (09) : 611 - 617
  • [8] The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
    Joyo, Yuji
    Kawaguchi, Yohei
    Yonezu, Hiroki
    Senda, Hiroya
    Yasuma, Sanshiro
    Shiraga, Hiroo
    Nozaki, Masahiro
    Aoyama, Mineyoshi
    Asai, Kiyofumi
    Murakami, Hideki
    Waguri-Nagaya, Yuko
    IMMUNOLOGIC RESEARCH, 2022, 70 (02) : 208 - 215
  • [9] The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
    Yuji Joyo
    Yohei Kawaguchi
    Hiroki Yonezu
    Hiroya Senda
    Sanshiro Yasuma
    Hiroo Shiraga
    Masahiro Nozaki
    Mineyoshi Aoyama
    Kiyofumi Asai
    Hideki Murakami
    Yuko Waguri-Nagaya
    Immunologic Research, 2022, 70 : 208 - 215
  • [10] The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study
    Calvo-Garcia, Alberto
    Herraiz, Esther Ramirez
    Cubas, Irene Maria Llorente
    De Dios, Blanca Varas
    Gonzalez, Juana Benedi
    Baladron, Alberto Morell
    Garcia-Vicuna, Rosario
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
12345